HIV Dementia among HIV Positive People at Debre Markos Hospital, Northwest Ethiopia
American Journal of Psychiatry and Neuroscience
Volume 2, Issue 2, March 2014, Pages: 18-24
Received: Jun. 30, 2014; Accepted: Jul. 18, 2014; Published: Jul. 30, 2014
Views 3901      Downloads 250
Authors
Tilahun Belete Mossie, Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia
Addisu Workineh Kassa, Amhara Region Health Bureau, Bahir Dar, Ethiopia
Minale Tareke Tegegne, Dessie Referral Hospital, Dessie, Ethiopia
Article Tools
Follow on us
Abstract
Background: HIV dementia which impairs life by causing learning, memory, behavioral and motor disabilities is still a particular problem in the HAART era. It has been prevalent particularly in the third world and specifically in sub Saharan Africa where limited access to diagnosis, treatment, care and support has been common. Hence the assessment of HIV dementia in one of the sub Saharan countries, namely Ethiopia, particularly in Debre markos referral hospital is important. Methods: A cross- sectional study design with descriptive and analytical components was employed on 423 participants with systematic random sampling technique (with proportional allocation). Data was collected by face to face interview, observation and document review using International HIV dementia scale translated into local language (Amharic version); then it was analyzed using SPSS window 20. The level of association was dealt using confidence interval and odds ratio. Result: the prevalence of HIV dementia was 24.8%. Having no education (AOR=3.11, 95% CI (1.37, 7.04)), older age of 50 years or above (AOR=4.25, 95% CI (1.05, 17.18)), having co morbid opportunistic infection (AOR=7.48, 95% CI (4.1, 13.64)) and substance use (AOR=4.64, 95% CI (2.3, 9.36)) were significantly associated with HIV dementia. Conclusion: Despite wide spread use of HAART, HIV dementia among HIV positive people is high when compared to worldwide figure. Having no education, older age of 50 years or more, being on HAART, having co morbid opportunistic infection, being in late stages of the illness and substance use were significantly associated with HIV dementia. Recommendation: starting HAART in those who developed opportunistic infection and in those 50 years or older PLHA should be considered regardless of the CD4 count.
Keywords
HIV Dementia, Neuro Cognitive Deficit, Neuro AIDS
To cite this article
Tilahun Belete Mossie, Addisu Workineh Kassa, Minale Tareke Tegegne, HIV Dementia among HIV Positive People at Debre Markos Hospital, Northwest Ethiopia, American Journal of Psychiatry and Neuroscience. Vol. 2, No. 2, 2014, pp. 18-24. doi: 10.11648/j.ajpn.20140202.11
References
[1]
Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Perez-Alvarez N, Molto J, Gomez G, Clotet B. Nadir CD4 count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008, 24(10):1301-1307
[2]
Wong M. Robertson K. Nakasujja N. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology. 2007;68:350-5
[3]
Gra F.Adle-Biassette H. Chrétien F. Lorin de la Grandmaison G. Force G. Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin. Neuropathol. 2001. 20 (4): 146-155. PubMed.
[4]
Adle-Biassette H. Lévy, Y. Colombel, M. Poron F. Natchev S. Keohane C. and Gray, F. Neuronal apoptosis in HIV infection in adults. Neuropathol. Appl. Neurobiol. 1995. 21 (3): 218-227. PubMed.
[5]
Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol. Feb 2007; 27(1):86-92. [Medline].
[6]
Benjamin J S & Virginia A S. Dementia. Synopsis of psychiatry.2007; 10th edition: 330-334
[7]
Sacktor NC. Wong M. Nakasujja N. et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-74
[8]
Wong M. Robertson R. Nakasujja N, Musisi S. Katabira E. McArthur J. et al. HIV-associated neurological complications among HIV-Seropositive individuals in Uganda. Neurology. 2004; 62:444
[9]
Antinori A. Arendt G. Becker JT. et al. Updated research nosology for HIV-associated neurocognitive disorders (HAND).Neurology 2007;69:1789-99
[10]
[10]. Price RW. Brew BJ. The AIDS dementia complex. Infectious Diseases. 1988;158:1079-83
[11]
Kiwanuka N. Laeyendecker O. Robb M. Effect of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIV-1 Infection. Infect Dis 2008; 197:707-13
[12]
Kaleebu P. French N. Mahe C. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-50.
[13]
Vasan A. Renjifo B. Hertzmark E. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-52.
[14]
Kanki PJ. Hamel DJ. Sankale JL. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73
[15]
Kaleebu P. Nankya IL. Yirrell DL. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
[16]
Dore GJ. Marked improvement in survival following AIDS dementia complex in the era of HAART. AIDS. July 4, 2003; 17(10):1539-45
[17]
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Neurovirol. 2002; 8 (2):115–121.
[18]
McDermott MP, Sacktor N, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136–142.
[19]
Dougherty RH. Progression of HIV associated dementia treated with HAART. AIDS. February 2002; 12(2): 69-74
[20]
UNAIDS. New HIV infection and AIDS related deaths. World AIDS day Report. 2011; 06-7
[21]
Jamnshi A.K. Risk factors for HIV associated neurocognitive disorders in Sub-Saharan Africa: The case of Yaounde-Cameroon. Journal of the neurological sciences. October 15, 2009; 1-2(285):149 – 153
[22]
Wadia, R. S., Pujari, S. N., Kothari, S., Udhar, M., Kulkarni,et al. Neurological manifestations of HIV disease. HIV/AIDS. J. Assoc. Physicians India. 2001, 49: 343-348
[23]
Federal ministry of health. Single point HIV prevalence Estimate. AIDS in Ethiopia: 6th report.2007 Available at: http://www.etharc.org/aidsineth/publications/singlepointprev2007.pdf
[24]
Federal HIV/AIDS prevention and control office. Status of the HIV/AIDS epidemic. Report on progress towards implementation of the UN Declaration of commitment on HIV/AIDS. March 2010; 06- 07
[25]
Debre Markos University. About city of Debre Markos. The foundation of Debre Markos town and its overall picture today.December8, 2011 Available at: http://www.dmu.edu.et/?q=node/135
[26]
Ministry of education & ministry of capacity building. University capacity building program. Debre Markos. July 2011 Available at http://www.ucb-ethiopia.com/e548/e572/e1061/
[27]
Ethiopian central statistics agency & ICF international. Key findings. 2011 Ethiopian demographic and heath survey. Calverton, Maryland, USA. 2012
[28]
Patel VN, Mungwira RG, Tarumbiswa TF, Heikinheimo T, van Oosterhout JJ. High prevalence of suspected HIV-associated dementia in adult Malawian HIV patients. Department of Medicine, university of Malawi. Pub Med. May 2010;21(5):356-8
[29]
Kathy L, Mosepele M, Sarah R, Esther S, Katherine S, et al. Neurocognitive impairment among HIV-positive individuals in Botswana. Journal of the International AIDS Society. 2010, 13(15);10,1186/1758-2652
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186